<div id="readability-page-1"><p>In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Moleculin Biotech, with a price target of <span id="expert-recommendation-target">$22.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Sara Nik’s rating is based on the promising progress of Moleculin Biotech’s Phase 3 MIRACLE study, which is evaluating annamycin for relapsed or refractory acute myeloid leukemia (r/r AML). The company has successfully enrolled 78% of the initial 45 patients, indicating strong momentum towards a significant data readout. This progress suggests that the company is nearing a pivotal point in its clinical execution, with the potential for impactful results.<br/>Sara Nik also highlights the strategic design of the study, which includes adaptive features and early unblinding points. These elements provide flexibility for potential regulatory feedback and adjustments during the trial, enhancing the likelihood of a successful outcome. If the initial data proves to be robust, it could lead to an accelerated New Drug Application process, further supporting the Buy rating for Moleculin Biotech’s stock.</p> </div>

MBRX

<p>Sara Nik from H.C. Wainwright reiterates a Buy rating for Moleculin Biotech, with a $22.00 price target, due to promising progress in their Phase 3 MIRACLE study for r/r AML. The study's strategic design and enrollment success suggest potential for impactful results and an accelerated New Drug Application process.</p>

Promising Progress in Moleculin Biotech’s Phase 3 MIRACLE Study Boosts Buy Rating